Raia Drogasil’s stock fell **36.4% year-to-date in 2026** as investors questioned its **digital transformation strategy** and reliance on an **aging customer base**. Analysts who delayed exposure early in the year avoided losses, despite Q3 2026 showing **revenue and profit growth**. The discrepancy highlights conflicting assumptions about the company’s long-term resilience and execution risks in its core business model.
RD Saúde, the owner of pharmacy chains Raia and Drogasil, reports a 9.2% year-over-year increase in adjusted profit for Q3 2026, reaching 439 million reais (US$80 million). The company also sees a 16% rise in sales during the same period. The adjusted profit excludes one-off financial items.
Raia Drogasil reports an **18.3% sales increase** in Q2 2026, driven by strong revenue growth as Brazil’s largest pharmacy chain. Despite the surge, **profit growth slows to 7.4%** due to rising operational costs squeezing margins. The company’s expansion continues, but cost pressures limit profitability gains.
RD Saúde reports accelerating digital platform adoption in Q3 2025, driven by increased telemedicine consultations and digital health tool usage. The company attributes growth to expanded partnerships with healthcare providers and rising demand for remote care solutions. Financial details from the earnings call underscore the shift toward digital-first services.
Raia Drogasil reports a 48% rise in second-quarter adjusted net profit. The Brazilian pharmacy chain highlights stronger financial performance in its latest earnings update. No additional operational details were provided in the brief report.